The major, Switzerland-based, global pharmaceutical company Novartis has just agreed to acquire Endocyte — the developer of both Lu-177- PSMA-617 and Ac-225-PSMA-617, which are in clinical trials for the treatment of advanced forms of prostate cancer. The fact that Novartis was willing to pay something like US$2.1 billion to acquire Endocyte probably tells us something about their confidence that one or both of these products will be coming to market in the next few years!
This is especially true when one realizes that, not so long ago, Novartis also paid US$3.9 billion to acquire a different company (Advanced Accelerator Applications) through which the Swiss drugmaker gained Lutathera (lutetium Lu-177 dotatate), which is already approved in both the US and Europe for the treatment of a relative rare group of cancers known as somatostatin-receptor positive gastroenteropancreatic neuroendocrine tumors.
For additional information about this acquisition, see here, or see the Novartis media release.
Filed under: Drugs in development | Tagged: Endocyte, Lu-177. Ac-225, Novartis, PSMA, radiopharmaceutical |
THE "NEW" PROSTATE CANCER INFOLINK 
Leave a Reply